^
Association details:
| Biomarker: | DDR2 overexpression |
|---|---|
| Cancer: | Squamous Cell Carcinoma of Head and Neck |
| Drug: | dasatinib (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Targeting DDR2 in head and neck squamous cell carcinoma with dasatinib
Excerpt:
DDR2 expression was assessed on a large HNSCC cohort (554 patients) including primary tumors, lymph node metastases and recurrences and normal mucosa as control...Our data suggest treatment with dasatinib as a promising new therapeutic option for patients suffering from DDR2 overexpressing HNSCC.
DOI:
10.1002/ijc.30279